Russell Investments Group Ltd. Has $1.75 Million Position in Cellebrite DI Ltd. $CLBT

Key Points

• Russell Investments Group Ltd. decreased its stake in Cellebrite DI Ltd. by 40.3%, selling 60,604 shares to hold a total of 89,812 shares valued at approximately $1.75 million.
• Multiple large investors adjusted their positions, with Wells Fargo & Company increasing its stake by 76.3%, while new positions were also established by Aquatic Capital Management and others totaling approximately $2.2 million.
• Analysts have lowered price targets for Cellebrite DI, with ratings ranging from "buy" to "overweight," reflecting a consensus rating of "Buy" and a target price of $22.40.

Russell Investments Group Ltd. lessened its position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 40.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 89,812 shares of the company's stock after selling 60,604 shares during the period. Russell Investments Group Ltd.'s holdings in Cellebrite DI were worth $1,745,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Teacher Retirement System of Texas raised its position in Cellebrite DI by 121.3% in the first quarter. Teacher Retirement System of Texas now owns 44,407 shares of the company's stock worth $863,000 after acquiring an additional 24,337 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Cellebrite DI by 19.3% during the 4th quarter. California State Teachers Retirement System now owns 71,385 shares of the company's stock valued at $1,573,000 after purchasing an additional 11,555 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Cellebrite DI in the 1st quarter worth approximately $269,000. Bank of America Corp DE raised its holdings in shares of Cellebrite DI by 32.0% in the 4th quarter. Bank of America Corp DE now owns 680,375 shares of the company's stock worth $14,989,000 after purchasing an additional 165,116 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Cellebrite DI by 32.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 148,132 shares of the company's stock valued at $3,263,000 after purchasing an additional 36,341 shares during the last quarter. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Down 1.9%

Shares of Cellebrite DI stock traded down $0.31 during midday trading on Monday, hitting $16.40. The company's stock had a trading volume of 1,961,581 shares, compared to its average volume of 2,462,044. The firm has a market capitalization of $3.93 billion, a P/E ratio of -21.58, a PEG ratio of 2.98 and a beta of 1.28. The stock has a 50-day simple moving average of $15.00 and a 200-day simple moving average of $17.10. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million for the quarter, compared to analyst estimates of $112.33 million. During the same period in the previous year, the firm earned $0.10 earnings per share. Cellebrite DI's quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on CLBT shares. Wall Street Zen upgraded shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. reduced their price objective on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Needham & Company LLC cut their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, August 14th. Finally, Lake Street Capital reduced their target price on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.